sorafenib has been researched along with Schistosoma japonicum Infection in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y | 1 |
1 other study(ies) available for sorafenib and Schistosoma japonicum Infection
| Article | Year |
|---|---|
Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.
Topics: Actins; Animals; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Praziquantel; Receptor, Platelet-Derived Growth Factor beta; Schistosoma japonicum; Schistosomiasis japonica; Sorafenib | 2018 |